Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Flip angle in susceptibility-weighted imaging for the diagnosis of multiple sclerosis - Authors' reply.
Flip angle in susceptibility-weighted imaging for the diagnosis of multiple sclerosis.
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis.
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis - Authors' reply.
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis.
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis.
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis.
Toxocara seropositivity in sensory-predominant cervical myelitis from an endemic region: A six-case series and systematic review.
Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis.
Drug-induced sarcoidosis-like reaction following IL-4/IL-13 receptor blockade by dupilumab.
Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.
Pages
« first
‹ previous
…
829
830
831
832
833
834
835
836
837